Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Radiation in Unresectable Esophageal Cancer
NCT03187314Phase 2Completed
- Start
- Jun 2017
- Primary completion
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Objective Response Rate. Started Jun 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03187314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187314.